RecruitingPhase 3NCT07227402
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Merck Sharp & Dohme LLC
- Principal Investigator
- Medical DirectorMerck Sharp & Dohme LLC
- Intervention
- Belzutifan(drug)
- Enrollment
- 904 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2032
Study locations (30)
- Hospital Aleman ( Site 0204), CABA, Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires. ( Site 0203), Caba, Buenos Aires, Argentina
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Caba, Buenos Aires, Argentina
- Instituto Alexander Fleming ( Site 0202), CABA, Buenos Aires, Argentina
- Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC) ( Site 0208), Caba., Buenos Aires F.D., Argentina
- Sanatorio Parque ( Site 0201), Rosario, Santa Fe Province, Argentina
- Instituto de Oncología de Rosario ( Site 0209), Rosario, Santa Fe Province, Argentina
- Hospital Privado Universitario de Córdoba ( Site 0207), Córdoba, Argentina
- Macquarie University-MQ Health Clinical Trials Unit ( Site 2100), Sydney, New South Wales, Australia
- Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0600), Linz, Upper Austria, Austria
- Medizinische Universitat Wien ( Site 0601), Vienna, Austria
- Cliniques Universitaires Saint-Luc ( Site 0703), Brussels, Bruxelles-Capitale, Region de, Belgium
- Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 0701), Genk, Limburg, Belgium
- UZ Gent ( Site 0702), Ghent, Oost-Vlaanderen, Belgium
- UZ Leuven ( Site 0700), Leuven, Vlaams-Brabant, Belgium
- +15 more locations on ClinicalTrials.gov
Collaborators
Exelixis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07227402 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)
- RECRUITINGNANCT06722807ClAmpless, Sutureless PartIAl Nephrectomy for Renal MassesUniversity of Florida